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Introduction: Hydrogen sulﬁde (H2S) known as a gasotransmitter is increasingly recognized for its anti-adhesive,
anti-inﬂammatory and vasoactive properties. Due to these properties,we analysed anti-thrombotic effects ofH2S
and the participation of the nitric oxide synthase (NOS)-pathway.
Materials and Methods: In individual venules of the ear of hairless SKH1-hr mice, thrombus formation was in-
duced using a phototoxic light/dye-injury model and intravital ﬂuorescence microscopy. Animals were treated
intravenously with the H2S donor Na2S or NaCl as control. In a second setting, the NOS inhibitor L-NAME was
applied intraperitoneally as a bolus 12 h prior to Na2S treatment and thrombus induction. Blood and ear tissue
were sampled after microscopy for assessment of plasma concentrations of soluble (s)P-selectin, sE-selectin,
sVCAM-1 and sICAM-1 and expression of endothelial (e)NOS and inducible (i)NOS, respectively.
Results:When mice were treated with Na2S, venular thrombus formation was signiﬁcantly delayed versus that
in animals of the NaCl-treated control group. While plasma levels of pro-thrombotic adhesion molecules were
not affected by Na2S, immunohistochemistry of the vessel walls showed a signiﬁcant up-regulation of eNOS and
iNOS expression within the Na2S-treated group. The delay of thrombus formation in the Na2S-group was partly
but signiﬁcantly reverted by application of L-NAME.
Conclusions: The anti-thrombotic efﬁcacy of H2S involves the NOS-pathway and may be of preventive and ther-
apeutic value for clinical disorders with increased risk of thrombotic events.© 2013 The Authors. Published by Elsevier Ltd. All rights reserved.Introduction
Thrombus formation and thrombosis related complications such
as pulmonary embolism are still a major cause of morbidity and mor-
tality and result from the coincidence of multiple disorders of
haemostasis and endothelial lesions with inﬂammation. Further, mul-
tiple risk factors, like immobilization after trauma, apoplexy and dailybon monoxide; H2S, hydrogen
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well as lifestyle risk factors with smoking, contraceptive drug intake,
metabolic syndrome and drug abuse are able to trigger thrombus for-
mation. Despite prophylactic treatment, thrombotic events display a
major cause of in-hospital lethality, especially after major surgery,
such as prosthetic knee and hip joint implantation, in elderly patients.
Due to limitations of the most common anti-coagulant substances [1]
there is a need for new anti-coagulants with more beneﬁt and less
side effects for patients.
Hydrogen sulﬁde (H2S) is a gas, which is noted for its smell of rotten
eggs and has traditionally been known as an air pollutant and poisonous
gas [2,3]. In the past, however, the physiological relevance of H2S gained
more recognition as it was detected in various mammalian tissues, me-
diating cytoprotective and pleiotropic effects [2–4]. H2S is enzymatically
synthesized by the two pyridoxal-5-phosphate-dependent enzymes,
i.e. cysthathionine-γ-lyase (CSE) and cystathionine-ß-synthase (CBS)
[5]. 3-mercaptopyruvate sulfurtransferase (3-MST) along with cysteine
aminotransferase is a further H2S-producing enzyme, as demonstrated
by Kimura [6]. Most recently, 3-MST together with D-amino acid oxi-
dase emerged as the fourth way for endogenous H2S production from
D-cysteine, predominantly in the cerebellum and the kidney [7].
There are at least twomechanisms for the release of H2S. First, H2S
is immediately released after its production by enzymes. Anotherserved.
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sulfane sulfur bond and is released in response to a physiological sig-
nal [8]. Endogenous H2S concentrations in human plasma are de-
scribed with a range from 34 μM to 65 μM [9]. H2S easily permeates
through biological membranes due to its lipophilic solubility and dis-
sociates to hydrosulﬁde and sulﬁde ions. In aqueous solution, about
one-third of H2S remains undissociated at physiological pH values
[4]. Next to nitric oxide (NO) and carbon monoxide (CO), H2S has
been recommended to be the third gasotransmitter [3,4]. As the re-
search in gas biology commenced with NO some 30 years ago, it has
become clear that cells are caught in the crossﬁre of different gaseous
transmitters. NO and CO share similar biological effects, including va-
sodilatation as well as inhibition of platelet aggregation and leukocyte
adhesion. The study on H2S is at an earlier stage, but seems to resem-
ble the speciﬁc effects of both other gases [10–12]. In line with this,
H2S is suggested to play an important role in vascular homeostasis
[13,14] as well as in anti-inﬂammation and anti-adhesion [2,15].
While most studies so far focus on inﬂammatory processes, organ
cell injury and postischemic reperfusion disorders [2], there are only
a few studies addressing the anti-aggregatory and anti-coagulatory
effects of H2S [16,17]. Most recently our group could demonstrate
that a slow releasing H2S donor acts anti-thrombotic by reduction of
platelet adhesion molecule expression and platelet granule exocyto-
sis [17]. However, the effects of H2S on the complex coagulation sys-
tem could be manifold due to its pleiotropic character. To further
extend the knowledge about the mechanisms of H2S on microvascu-
lar thrombus formation, the current study addresses the interactions
of H2S with the vascular endothelium, focusing on its anti-thrombotic
property mediated by the synthesis and release of NO.
Materials and Methods
Animals
23 female SKH1-hr hairless mice (10 to 12 weeks old with a body
weight (bw) of 22 to 26 g) were purchased from Charles River Labo-
ratories (Sulzfeld, Germany). The animals were housed in a speciﬁc
pathogen free facility with a 12 h light-dark cycle and had access to
standard laboratory chow and water ad libitum. The experiments
were conducted in accordance with the German legislation on protec-
tion of animals and the NIH Guide for the Care and Use of Laboratory
Animals (Institute of Laboratory Animal Resources, National Research
Council).
Chemicals
The H2S donor sodium sulﬁde (Na2S; Sigma Chemical, Deisenhofen,
Germany) was dissolved in physiological saline to a stock solution of
5 mmol x l-1 and was infused intravenously at a concentration of
125 μmol x kg-1 bwx h-1. The unspeciﬁc nitric oxide synthase (NOS) in-
hibitor L-NAME (NG-nitro-L-arginin-methylester) was dissolved in
physiological saline to a concentration of 100 mg x kg-1 bw andwas ad-
ministered intraperitoneally 12 h prior to the experiment (Sigma
Chemical). All solutions were freshly prepared at the day of the experi-
ment. Dose and application mode of drugs were chosen in accordance
to previous work of our group [18,19].
In Vivo Thrombosis Model
Mice were anesthetized by an intraperitoneal injection of keta-
mine (90 mg x kg-1 bw) and xylazine (25 mg x kg-1 bw) and placed
on a plexiglas pad with an integrated heating plate for maintaining
the body temperature at 37 °C. The ear was spread cautiously into
position with the help of a moisturized translucent plastic wrap for
visualization of the microcirculation by intravital ﬂuorescence mi-
croscopy (Axiotech vario; Zeiss, Jena, Germany) equipped with a100 W mercury lamp and a blue ﬁlter set (465-495 nm/N505 nm
excitation/emission wavelength). Thrombus induction and intravital
microscopy of the ear of the mouse were conducted upon injection of
0.1 ml 5 % ﬂuorescein isothiocyanate-labeled dextran (FITC-dextran)
(MW 150 kDa; Sigma) via a venous jugular catheter. The present
thrombus model has the advantage that there is no need for any surgi-
cal preparation to investigate the microcirculation within the ear.
Therefore, thrombus induction is not affected by inﬂammation due to
a surgical trauma and can be studied under almost physiological condi-
tions. Photochemical thrombus formation was induced by continuous
blue light exposure to individual venules using an x63water immersion
objective lens (Zeiss). Up to ﬁve venules (diameter range 45 to 75 μm)
per ear were studied. Light exposure started 10 min after start of the
continuous Na2S or NaCl infusion and was discontinued after blood
ﬂow in the vessel ceased for at least 30 s due to complete vessel occlu-
sion. Microscopic images were recorded by a video system (S-VHS
Panasonic AG 7350-E, Matsushita, Tokyo, Japan) for off-line evaluation
using a charge-coupled device video camera (FK 6990A-IQ, Pieper,
Berlin, Germany) and were monitored on a television screen.
Experimental Design and Experimental Groups
The following three groups of animals were studied: a saline-
treated control group (n = 8), a Na2S-treated group (n = 10) and a
Na2S + L-NAME-treated group (n = 5). Ten minutes before induc-
tion of thrombus formation intravenous infusion via the venous jugu-
lar catheter of either Na2S (125 μmol x kg-1 bw x h-1; Na2S) or
equivalent volumes of physiological saline (control) was started and
continued until the end of the experiment. The third group received
a continuous infusion of Na2S, as described, but was pre-treated
with a single intraperitoneal bolus of L-NAME (100 mg x kg-1 bw)
12 h prior to the experiments (Na2S + L-NAME).
Microcirculatory Analysis
Microcirculatory parameters, such as initial vessel diameter (D),
red blood ﬂow velocity (vRBC) and wall shear rate (γ) were assessed
prior to the thrombus induction. The calculation of the wall shear
rate is based on the Newtonian deﬁnition γ = 8 × vRBC × D-1, with
vRBC representing the red blood cell centerline velocity divided by
1.6, according to the Baker-Wayland factor [20] and D representing
the individual inner vessel diameter. Analysis of kinetics of thrombus
formation included the time periods until initial occlusion of perfu-
sion and sustained cessation of blood ﬂow due to complete vessel
occlusion. Time periods were assessed off-line by analyzing the
videotaped images using the image analyzing system CapImage
(Dr. Zeintl software, Heidelberg, Germany). If a vessel did not occlude
within 25 min of continuous light exposure, observation was stopped
and the vessel was considered as patent.
Histology and Immunohistochemistry
At the end of the experiments both ears of all animals were sampled
and ﬁxed in 4% phosphate buffered formaldehyde for 2 to 3 days. After
parafﬁn embedding tissue blocks were cut in 4 μm slices and stained
with hematoxylin-eosin for routine histological analysis. For immuno-
histochemical demonstration of eNOS and iNOS, tissue sections collect-
ed on poly-L-lysine-coated glass slides were treated by microwave for
antigen unmasking. A mouse anti-mouse eNOS and a rabbit anti-
mouse iNOS antibody (both Calbiochem, Darmstadt, Germany) were
used as primary antibodies at dilutions of 1:50 (eNOS) and 1:500
(iNOS) and incubated overnight at 4 °C, followed by incubation with
the appropriate secondary horseradish-peroxidase labeled antibodies
in accordance to the instructions of the LSAB + System HRP kit
(DAKO, Hamburg, Germany) and development using ACE as chromo-
gen. The sectionswere counterstainedwith hematoxylin and examined
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titative analysis staining intensity of the venular walls has been catego-
rized into four scoring levels: 0 corresponded to no staining, 1 to faint
staining, 2 to moderate staining and 3 to intense staining.
ELISA
Plasma concentrations of circulating sICAM-1, sVCAM, sP-selectin
and sE-selectin were determined using the respective enzyme immu-
noassay kits (R&D Systems, Abingdon, Great Britain). Blood samples
were prepared by centrifugation for 10 min at 3500 g and room tem-
perature (GS-6R Centrifuge, Beckmann Coulter, Fullerton, CA).
Statistics
Statistical analysis was performed after proving the assumption of
normality and equal variance across all groups. Differences between
the groups were assessed using one way ANOVA followed by the
appropriate post-hoc comparison test. All data revealed normal dis-
tribution and were expressed as mean ± SEM. Overall statistical sig-
niﬁcance was set at p b 0.05. Statistics and graphics were performed
using the software packages SigmaStat and SigmaPlot (Jandel Corpo-
ration, San Rafael, CA, USA).
Results
In NaCl-treated animals, light/dye phototoxicity caused a throm-
bus formation in all venules studied (Fig. 1, A and B). Initial occlusion
of perfusion was found at 124 ± 8 s (Fig. 2A) and resulted in com-
plete vessel occlusion at 165 ± 17 s (Fig. 2B). In contrast to that,
the H2S donor Na2S caused a signiﬁcant prolongation in the kinetics
of thrombus formation with average values of 404 ± 124 s and
686 ± 98 s for the initial occlusion of perfusion (Fig. 2A) andFig. 1. Intravital ﬂuorescence microscopic images of the microcirculatory network of
the mouse ear with a draining venule (A) before and (B) after thrombus induction.
FITC-dextran and blue-light epi-illumination using a 10-fold magniﬁcation.complete vessel occlusion (Fig. 2B), respectively. In animals, which
were blocked for NO-synthases by application of the unspeciﬁc inhib-
itor L-NAME, the anti-thrombotic action of Na2S was partly reverted.
This is reﬂected by an average time of initial occlusion of perfusion of
260 ± 49 s (Fig. 2A) and of complete vessel occlusion of 388 ± 48 s
(Fig. 2B).
While in NaCl- and Na2S + L-NAME-treated animals all vessels (37
out of 37 and 20 out of 20) could be occluded upon blue light exposure,
20% of all vessels studied (6 out of 30 vessels) in the Na2S-treated ani-
mals remained patent throughout the illumination process, further
underlining the anti-thrombotic efﬁcacy of H2S.
By assessing the microhemodynamics within the ear’s microcircu-
lation, we could demonstrate no signiﬁcant differences between the
three groups with respect to vessel diameter and calculated wall
shear rate (Table 1). In the Na2S + L-NAME-treated animals, vRBC
was found signiﬁcantly lower compared to the Na2S-treated mice
(Table 1).
Using immunohistochemistry, vascular eNOS and iNOS expression
was studied and semiquantitatively assessed. Staining intensity of
both eNOS and iNOS expression was found more intense in the
Na2S-treated animals when compared to NaCl-treated mice, as illus-
trated in Fig. 3. Semiquantitative analysis revealed a score of
1.88 ± 0.10 (eNOS) and of 2.37 ± 0.10 (iNOS) for the Na2S-treated
mice compared to 1.54 ± 0.11 and 1.53 ± 0.09 (eNOS and iNOS)
for the NaCl-treated mice (p b 0.05; Fig. 3, G and H), conﬁrming
the qualitative impression. Upon concomitant application of the
NOS-inhibitor L-NAME, both eNOS and iNOS expression was marked-
ly reduced with scores of 0.47 ± 0.08 (p b 0.001 vs NaCl and Na2S)
and of 0.77 ± 0.10 (p b 0.001 vs NaCl and Na2S).
No differences in the endothelial cell activation markers, like
sP-selectin, sE-selectin, sVCAM-1 and sICAM-1 concentrations in plas-
ma, were found between the animals of the three groups studied
(data not shown).
Discussion
During the last decade the concept of gasotransmitters has been
appreciated, introducing membrane receptor-independent signaling
mechanisms in the vascular (patho)physiology [2,3]. NO and CO
have been identiﬁed as the ﬁrst two gasotransmitters and were
followed by H2S, being entitled as the third gasotransmitter. Like NO
and CO, H2S fulﬁlls the classical criteria of a gasotransmitter, i.e. it
(i) is a small gas molecule, (ii) is freely permeable to membranes,
(iii) is endogenously and enzymatically synthesized and regulated,
and (iv) exerts deﬁned functions in physiological concentrations,
which may or may be not mediated by second messengers, but
(v) has speciﬁc cellular and molecular targets [2].
H2S exerts a classical pleiotropic proﬁle with anti-inﬂammatory,
anti-apoptotic and cytoprotective properties in various animal dis-
ease models [5,13,21,22]. Besides that, H2S has been shown to play
a major regulatory role in the cardiovascular system, including
platelet aggregation. So, Zagli and coworkers, using sodium hydrogen
sulﬁde (NaHS) as H2S donor, demonstrated in vivo that H2S inhibits
human platelet aggregation induced by various agonists, like ADP,
collagen, arachidonic acid, and thrombin [16]. In addition, H2S
was shown to inhibit the adhesion and activation of neutrophil
granulocytes [13]. As both processes represent key events in throm-
bus formation, it is reasonable to deduce that herein observed prolon-
gation of thrombus formation by H2S can mainly be attributed to its
anti-aggregatory and anti-adhesive action.
The formation of an initial thrombus at site of endothelial damage
takes place in the ﬁrst step of hemostasis. This primary hemostasis is
characterized by the rolling, adhesion and aggregation of activated
platelets on endothelial cells or subendothelial structures and is me-
diated by adhesion molecules like P-selectin, GPIb and GPIIb/IIIa. Re-
cently, we were able to show that H2S exposure of platelets leads to
Fig. 2. Quantitative analysis of (A) the time until initial occlusion of perfusion and (B) the time for complete vessel occlusion in venules upon phototoxic light/dye thrombus induc-
tion in the mouse ear model. Animals received either physiological saline as control (n = 8), Na2S (n = 10) or Na2S + L-NAME (n = 5). ANOVA, post hoc comparison; mean ± SEM:
* p b 0.05 vs NaCl.
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ceptors [17]. The current ﬁndings conﬁrm the anti-thrombotic effect
of H2S on thrombus formation in another thrombosis model and dis-
play the prolonged time until ﬁrst sufﬁcient thrombotic vessel occlu-
sion as a possible consequence of the reduced expression of adhesion
molecules on activated platelets.
The mechanisms of the actions explicated by H2S are multiple and
range from vasodilation and activation of KATP-channels to the differ-
ential regulation of pro- and anti-inﬂammatory genes [2]. Thereby,
most effects of H2S are based on the post-translation modiﬁcation of
protein functions through S-sulfhydration [23]. This process might
also be involved in the modiﬁcation of platelet activity, as platelet
proteins exert an increased S-sulfhydration after treatment with H2S
[17]. In addition, a major body of evidence exists for a complex inter-
action between NO and H2S in regulating cellular functions, cardio-
vascular responses and inﬂammatory/immune functions [2–4,6].
There is a synergy of NO and H2S on vascular smooth muscle relaxa-
tion and the cysteine residues of the H2S producing enzyme CSE are
potential targets for NO-induced S-nitrosylation, thereby enhancing
the activity of CSE [24]. Beside the direct action of NO on CSE protein,
NO stimulates CSE by increasing the activity of cGMP-dependentTable 1
Microvascular hemodynamics.
NaCl Na2S Na2S + L-NAME
diameter [μm] 57 ± 3 60 ± 4 58 ± 3
vRBC [μm/s] 515 ± 61 624 ± 61 444 ± 49#
wall shear rate [s-1] 47 ± 7 56 ± 7 40 ± 6
Microhemodynamics in venules of the cutaneous microcirculation in the ear of the
mouse in animals, which received either physiological saline as control, Na2S or
Na2S + L-NAME. vRBC, red blood ﬂow velocity. ANOVA, post hoc comparison;
mean ± SEM: # p b 0.05 vs Na2S.kinases [14]. Vice versa, H2S upregulates the NO production from
eNOS through Akt kinase-dependent Ser 1177 phosphorylation [25].
In addition, H2S augments NO production by potentiating the
IL-1β-induced NFκB activation in rat vascular smooth muscle cells
and this is associated with increased expression of iNOS, though H2S
by itself has no effect on NO production from rat vascular smooth mus-
cle cells [26]. There are further studies showing that theH2S-induced in-
crease of the duodenal HCO3- secretion is partly mediated by NO [27]
and that Na2S increases the phosphorylation of eNOS in the left ventri-
cle of mice undergoing cardiac arrest and resuscitation [28]. In linewith
this, we could demonstrate increased expression of eNOS and iNOS in
the Na2S-treated mice, underscoring the cooperative network of NO
and H2S to regulate their effects. Although eNOS and iNOS staining in-
tensity was assessed by using a semiquantitative score which does not
allow to verify ﬁnal enzyme expression levels, as western blotting or
real-time PCR data would, immunohistochemistry allowed the mor-
phological allocation of the NO synthases to endothelial and vascular
smooth muscle cells of the ear tissues.
The close crosstalk of these two gaseousmediators is further featured
by a variety of studies demonstrating thatH2Smediates its cytoprotective
and vasoactive properties at least partly by an NO-dependent mecha-
nism. For example, preconditioning of the post-ischemic small intestine
by H2S inhibited post-ischemic leukocyte-endothelial cell interaction
and this effect was absent in eNOS knockoutmice or abolished by coinci-
dent pharmacological inhibition of NOS in wildtype animals [29]. More-
over, eNOS deﬁciency abrogated the protective effects of Na2S on the
outcome after cardiac arrest and cardiopulmonary resuscitation [28].
In compliance with this, the current study demonstrates that the
anti-thrombotic action of H2S, i.e. prolonging the time until both initial
occlusion of blood ﬂow and complete thrombotic vessel occlusion, is
partly reverted upon concomitant NOS blockade by L-NAME application.
The less prolonged thrombus formation after L-NAME treatment of Na2-
S-exposed mice can be explained by lack of NO due to the property of
Fig. 3. Representative images of (A-C) eNOS expression and (D-F) iNOS expression in venular vessels (arrows) of the cutaneous microcirculation at the ear of the mouse (40-fold
magniﬁcation) aswell the corresponding semiquantitative analysis of (G) eNOS expression and (H) iNOS expression. Animals received either physiological saline as control (n = 8), Na2S
(n = 10) or Na2S + L-NAME (n = 5). ANOVA, post hoc comparison; mean ± SEM: * p b 0.05 vs NaCl; # p b 0.05 vs Na2S.
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thrombus weight and expression of VCAM-1 [30].
Inhibition of NOS by L-NAME could only partly revert the anti-
thrombotic effect of Na2S. This can be explained by our recently pub-
lished data in the light/dye- and the FeCl3-thrombosis model in the
dorsal skinfold chamber preparation showing that the H2S donor
GYY4137 prolongs thrombus formation and further reduces the
exocytosis of platelet granules most probably by S-sulfhydration of
platelet proteins, thereby leading to a reduced expression of pro-
thrombotic adhesion molecules on activated platelets [17].
Under physiological conditions, the constitutively expressed
Ca2+-dependent eNOS is responsible for the continuous release of
NO by endothelial cells, contributing to the anti-thrombogenic
phenotype of the endothelium [31]. Expression of the inducible
Ca2+-independent iNOS is induced by a variety of injurious andpro-inﬂammatory stimuli in vascular smooth muscle cells and leads
to persistent generation of large quantities of NO [32]. There is plenty
and strong evidence for the deﬁnite inhibitory effects of NO on plate-
lets passing in close proximity to the endothelium [33,34], thereby
preventing platelet aggregation and thrombus formation. Thus, it is
reasonable to deduce that the mechanism underlying the delayed
thrombus formation by H2S partly involves NOS upregulation and in-
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